Anthera Pharmaceuticals Inc. said it achieved full compliance with all requirements for continued listing on the Nasdaq Capital Market.
The Hayward, Calif.-based biopharmaceutical company is now compliant with Nasdaq rules, including the $35 million market value of listed securities requirement.
Anthera's common stock was listed on the Nasdaq Capital Market on Jan. 26. The listing was subject to compliance with all of Nasdaq's requirements by May 14.
Anthera makes medicines for patients with unmet medical needs.
